AFT Pharmaceuticals Ltd. (NZ:AFT)
:AFT
Want to see NZ:AFT full AI Analyst Report?
Total Valuation
AFT Pharmaceuticals Ltd. has a market cap or net worth of $372.28M. The enterprise value is $397.00M.
Market Cap$372.28M
Enterprise Value$397.00M
Share Statistics
AFT Pharmaceuticals Ltd. has 104,866,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,866,260
Owned by Insiders69.92%
Owned by Institutions―
Financial Efficiency
AFT Pharmaceuticals Ltd.’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 6.48%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)6.48%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee1.87M
Profits Per Employee0.00
Employee Count110
Asset Turnover1.21
Inventory Turnover2.40
Valuation Ratios
The current PE Ratio of AFT Pharmaceuticals Ltd. is 22.2. AFT Pharmaceuticals Ltd.’s PEG ratio is -0.88.
PE Ratio22.2
PS Ratio1.37
PB Ratio2.89
Price to Fair Value2.89
Price to FCF45.32
Price to Operating Cash Flow45.35
PEG Ratio-0.88
Income Statement
In the last 12 months, AFT Pharmaceuticals Ltd. had revenue of 205.49M and earned 11.96M in profits. Earnings per share was 0.11.
Revenue205.49M
Gross Profit89.19M
Operating Income11.70M
Pretax Income16.03M
Net Income11.96M
EBITDA21.52M
Earnings Per Share (EPS)0.11
Cash Flow
In the last 12 months, operating cash flow was 8.21M and capital expenditures -195.00K, giving a free cash flow of 8.01M billion.
Operating Cash Flow8.21M
Free Cash Flow8.01M
Free Cash Flow per Share0.08
Dividends & Yields
AFT Pharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.03
52-Week Price Change38.17%
50-Day Moving Average3.55
200-Day Moving Average3.20
Relative Strength Index (RSI)55.18
Average Volume (3m)8.22K
Important Dates
AFT Pharmaceuticals Ltd. upcoming earnings date is May 25, 2026, After Close (Confirmed).
Last Earnings DateNov 19, 2025
Next Earnings DateMay 25, 2026
Ex-Dividend Date―
Financial Position
AFT Pharmaceuticals Ltd. as a current ratio of 2.50, with Debt / Equity ratio of 38.21%
Current Ratio2.50
Quick Ratio1.38
Debt to Market Cap0.09
Net Debt to EBITDA0.88
Interest Coverage Ratio4.15
Taxes
In the past 12 months, AFT Pharmaceuticals Ltd. has paid 4.63M in taxes.
Income Tax4.63M
Effective Tax Rate0.29
Enterprise Valuation
AFT Pharmaceuticals Ltd. EV to EBITDA ratio is 13.98, with an EV/FCF ratio of 48.35.
EV to Sales1.46
EV to EBITDA13.98
EV to Free Cash Flow48.35
EV to Operating Cash Flow22.84
Balance Sheet
AFT Pharmaceuticals Ltd. has $12.19M in cash and marketable securities with $37.87M in debt, giving a net cash position of -$25.68M billion.
Cash & Marketable Securities$12.19M
Total Debt$37.87M
Net Cash-$25.68M
Net Cash Per Share-$0.24
Tangible Book Value Per Share$0.37
Margins
Gross margin is 44.53%, with operating margin of 5.69%, and net profit margin of 5.82%.
Gross Margin44.53%
Operating Margin5.69%
Pretax Margin7.80%
Net Profit Margin5.82%
EBITDA Margin10.47%
EBIT Margin9.18%
Analyst Forecast
The average price target for AFT Pharmaceuticals Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast19.01%
EPS Growth Forecast50.32%